Budd-Chiari syndrome secondary prevention

Jump to navigation Jump to search

Budd-Chiari syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Budd-Chiari syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Budd-Chiari syndrome secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Budd-Chiari syndrome secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Budd-Chiari syndrome secondary prevention

CDC on Budd-Chiari syndrome secondary prevention

Budd-Chiari syndrome secondary prevention in the news

Blogs on Budd-Chiari syndrome secondary prevention

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Budd-Chiari syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mazia Fatima, MBBS [2]

Overview

Secondary prevention strategies following Budd-Chiari syndrome include various measures such as, initiation of anticoagulation immediately in patients to prevent propagation of the clot, provided there are no contraindications. Effective management of esophageal varices. Patients with Budd-Chiari syndrome treated with balloon dilatation or stents require follow-up catheterizations and repeat dilatations or stent replacement. All patients should have routine surveillance for hepatocellular carcinoma (HCC).

Secondary Prevention

Secondary prevention strategies following Budd-Chiari syndrome include: [1][2]

References

  1. Goel RM, Johnston EL, Patel KV, Wong T (2015). "Budd-Chiari syndrome: investigation, treatment and outcomes". Postgrad Med J. 91 (1082): 692–7. doi:10.1136/postgradmedj-2015-133402. PMID 26494427.
  2. Ren W, Qi X, Yang Z, Han G, Fan D (2013). "Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review". Eur J Gastroenterol Hepatol. 25 (7): 830–41. doi:10.1097/MEG.0b013e32835eb8d4. PMID 23411869.

Template:WS Template:WH